Email this article Biomarkers of prostate cancer sensitivity to the Sendai virus
- Authors: Belova A.A.1, Sosnovtseva A.O.1,2, Lipatova A.V.1, Njushko K.M.3, Volchenko N.N.3, Belyakov M.M.3, Sudalenko O.V.3, Krasheninnikov A.A.3, Shegai P.V.3, Sadritdinova A.F.1,3, Fedorova M.S.1, Vorobjov N.V.3, Alekseev B.Y.3, Kaprin A.D.3, Kudryavtseva A.V.1,3
-
Affiliations:
- Engelhardt Institute of Molecular Biology
- Pirogov Russian National Research Medical University
- National Medical Research Radiological Center
- Issue: Vol 51, No 1 (2017)
- Pages: 80-88
- Section: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/162962
- DOI: https://doi.org/10.1134/S0026893317010046
- ID: 162962
Cite item
Open Access
Access granted
Subscription Access
Abstract
Metastatic prostate cancer is often associated with either primary or intractable castration-resistant prostate cancer (CRPC), thus justifying the search for entirely new ways of treatment. Oncolytic viruses are able to selectively induce the death of tumor cells without affecting normal cells. A murine Sendai virus has potential to be used as an oncolytic agent. However, tumors vary in their sensitivity to different viruses, prompting us to attempt to identify corresponding biomarkers that reflect the interaction of cancer cells and the virus. Here, we show that the sensitivity of primary prostatic adenocarcinoma cell lines to Sendai virus strain (SeVM) vary substantially. Using quantitative PCR, we evaluated expression levels of genes that encode RIG-1-like and Toll-like receptors (TLRs) in cell lines and showed that the levels of mRNAs that encode TLR3 and TLR7 correlate with a degree of sensitivity of the cells to Sendai virus. The lines with lower levels of TLR3 and TLR7 expression are more sensitive to the virus.
About the authors
A. A. Belova
Engelhardt Institute of Molecular Biology
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 119991
A. O. Sosnovtseva
Engelhardt Institute of Molecular Biology; Pirogov Russian National Research Medical University
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 119991; Moscow, 117997
A. V. Lipatova
Engelhardt Institute of Molecular Biology
Author for correspondence.
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 119991
K. M. Njushko
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
N. N. Volchenko
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
M. M. Belyakov
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
O. V. Sudalenko
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
A. A. Krasheninnikov
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
P. V. Shegai
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
A. F. Sadritdinova
Engelhardt Institute of Molecular Biology; National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 119991; Moscow, 125284
M. S. Fedorova
Engelhardt Institute of Molecular Biology
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 119991
N. V. Vorobjov
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
B. Y. Alekseev
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
A. D. Kaprin
National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 125284
A. V. Kudryavtseva
Engelhardt Institute of Molecular Biology; National Medical Research Radiological Center
Email: lipatovaanv@gmail.com
Russian Federation, Moscow, 119991; Moscow, 125284
Supplementary files
